Asunto(s)
Conflictos Armados/estadística & datos numéricos , COVID-19/epidemiología , Infecciones por VIH/epidemiología , Tuberculosis/epidemiología , Fármacos Anti-VIH/provisión & distribución , COVID-19/diagnóstico , COVID-19/transmisión , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/prevención & control , Humanos , Programas de Inmunización/estadística & datos numéricos , Masculino , Sarampión/epidemiología , Sarampión/transmisión , Metadona/provisión & distribución , Tratamiento de Sustitución de Opiáceos , Poliomielitis/epidemiología , Poliomielitis/prevención & control , Poliomielitis/transmisión , Vigilancia en Salud Pública , Tuberculosis/tratamiento farmacológico , Tuberculosis/transmisión , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Ucrania/epidemiología , Vacunas Virales/administración & dosificación , Vacunas Virales/provisión & distribuciónRESUMEN
Despite its proven efficacy, buprenorphine remains dramatically underutilized for management of opioid use disorder largely due to onerous barriers to treatment initiation. During the COVID-19 pandemic, many substance use disorder treatment facilities have reduced their hours and services, exacerbating existing barriers. To this end, the U.S. Drug Enforcement Administration and Substance Abuse Mental Health Services Administration adjusted their guidelines to allow for new buprenorphine prescriptions following audio-only telehealth encounters, no longer requiring an in-person evaluation prior to treatment initiation. Under this new guidance, we established a 24/7 telephone hotline to function as a "tele-bridge" clinic where people with opioid use disorder can be linked with a buprenorphine prescriber in real-time for OUD assessment and unobserved buprenorphine initiation with connection to follow-up if appropriate. Additionally, we developed an ED callback protocol to reach patients recently seen for opioid overdose and facilitate their entry into care if interested. In this commentary we describe our hotline and ED callback protocols, discuss theoretical and anecdotal benefits to this approach, and advocate for continuation of current regulatory changes post-COVID-19 to maintain expanded access to novel treatment approaches.
Asunto(s)
Buprenorfina/uso terapéutico , COVID-19 , Accesibilidad a los Servicios de Salud , Metadona/uso terapéutico , Antagonistas de Narcóticos/uso terapéutico , Trastornos Relacionados con Opioides/tratamiento farmacológico , Telemedicina , Buprenorfina/provisión & distribución , Servicio de Urgencia en Hospital , Humanos , Metadona/provisión & distribución , Tratamiento de Sustitución de Opiáceos , Trastornos Relacionados con Opioides/rehabilitación , Rhode IslandRESUMEN
COVID-19 necessitated rapid changes in methadone take-home policies in opioid treatment programs (OTPs); these changes markedly contrast with existing, long-standing federal mandates on OTP rules about take-home methadone. OTP providers describe how these changes have affected clinical decision-making, equity in patient care, and workflow. We also discuss implications for medical ethics and patient autonomy. We provide suggestions for future research that will examine the impact of COVID-19 on OTP treatment and its patients, as well as the effect of making methadone take-home polices patient centered, all of which may foreshadow larger changes in the ways OTPs deliver their services.
Asunto(s)
COVID-19 , Toma de Decisiones Clínicas/ética , Personal de Salud/psicología , Metadona/uso terapéutico , Trastornos Relacionados con Opioides/tratamiento farmacológico , Accesibilidad a los Servicios de Salud , Humanos , Metadona/provisión & distribución , Tratamiento de Sustitución de Opiáceos , Trastornos Relacionados con Opioides/rehabilitación , Flujo de TrabajoRESUMEN
In the context of the COVID-19 pandemic and the state of emergency that the government of Spain declared, the rapid adaptation of health services is of paramount importance to preserve access to and continuity of service delivery. This research note underscores the importance of ensuring a sufficient quantity of methadone take-home doses for patients on methadone maintenance treatment (MMT) to maximize their adherence to government-imposed lockdown restrictions and social distancing measures designed to curtail the spread of SARS-CoV-2. We evaluate the impact of COVID-19 on take-home medication (number of days provided) in a methadone clinic in Barcelona (Catalonia, Spain). This work conveys that we should consider maintaining the take-home practices that we adopted in response to the pandemic, even after the pandemic has abated.
Asunto(s)
Infecciones por Coronavirus , Metadona/administración & dosificación , Tratamiento de Sustitución de Opiáceos/métodos , Trastornos Relacionados con Opioides/rehabilitación , Pandemias , Neumonía Viral , Instituciones de Atención Ambulatoria , COVID-19 , Accesibilidad a los Servicios de Salud , Humanos , Metadona/provisión & distribución , EspañaRESUMEN
Importance: While many individuals with opioid use disorder seek treatment at residential facilities to initiate long-term recovery, the availability and use of medications for opioid use disorder (MOUDs) in these facilities is unclear. Objective: To examine differences in MOUD availability and use in residential facilities as a function of Medicaid policy, facility-level factors associated with MOUD availability, and admissions-level factors associated with MOUD use. Design, Setting, and Participants: This cross-sectional study used deidentified facility-level and admissions-level data from 2863 residential treatment facilities and 232â¯414 admissions in the United States in 2017. Facility-level data were extracted from the 2017 National Survey of Substance Abuse Treatment Services, and admissions-level data were extracted from the 2017 Treatment Episode Data Set-Admissions. Statistical analyses were conducted from June to November 2019. Exposures: Admissions for opioid use disorder at residential treatment facilities in the United States that identified opioids as the patient's primary drug of choice. Main Outcomes and Measures: Availability and use of 3 MOUDs (ie, extended-release naltrexone, buprenorphine, and methadone). Results: Of 232â¯414 admissions, 205â¯612 (88.5%) contained complete demographic data (166â¯213 [80.8%] aged 25-54 years; 136â¯854 [66.6%] men; 151â¯867 [73.9%] white). Among all admissions, MOUDs were used in only 34â¯058 of 192â¯336 (17.7%) in states that expanded Medicaid and 775 of 40â¯078 (1.9%) in states that did not expand Medicaid (P < .001). A relatively low percentage of the 2863 residential treatment facilities in this study offered extended-release naltrexone (854 [29.8%]), buprenorphine (953 [33.3%]), or methadone (60 [2.1%]). Compared with residential facilities that offered at least 1 MOUD, those that offered no MOUDs had lower odds of also offering psychiatric medications (odds ratio [OR], 0.06; 95% CI, 0.05-0.08; Wald χ21 = 542.09; P < .001), being licensed by a state or hospital authority (OR, 0.39; 95% CI, 0.27-0.57; Wald χ21 = 24.28; P < .001), or being accredited by a health organization (OR, 0.28; 95% CI, 0.23-0.33; Wald χ21 = 180.91; P < .001). Residential facilities that did not offer any MOUDs had higher odds of accepting cash-only payments than those that offered at least 1 MOUD (OR, 4.80; 95% CI, 3.47-6.64; Wald χ21 = 89.65; P < .001). Conclusions and Relevance: In this cross-sectional study of residential addiction treatment facilities in the United States, MOUD availability and use were sparse. Public health and policy efforts to improve access to and use of MOUDs in residential treatment facilities could improve treatment outcomes for individuals with opioid use disorder who are initiating recovery.
Asunto(s)
Analgésicos Opioides/provisión & distribución , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Tratamiento de Sustitución de Opiáceos/estadística & datos numéricos , Trastornos Relacionados con Opioides/tratamiento farmacológico , Tratamiento Domiciliario/estadística & datos numéricos , Centros de Tratamiento de Abuso de Sustancias/estadística & datos numéricos , Buprenorfina/provisión & distribución , Estudios Transversales , Humanos , Medicaid , Metadona/provisión & distribución , Naltrexona/provisión & distribución , Estados UnidosRESUMEN
The United States continues to face a public health crisis of opioid-related harm, the effects of which could be dramatically reduced through increased access to opioid agonist therapy with the medications methadone and buprenorphine. Despite overwhelming evidence of their efficacy, unduly restrictive federal, state, and local regulation significantly impedes access to these life-saving medications. We outline immediate, concrete steps that federal, state, and local governments can take to change law from barrier to facilitator of evidence-based treatment for opioid use disorder. These include removing onerous restrictions on the prescription and dispensing of buprenorphine and methadone for opioid agonist therapy, requiring insurance coverage of these medications, and mandating that they be provided in correctional settings and promoted by drug courts. Finally, we argue that jurisdictions should proactively offer opioid agonist therapy to individuals at high risk of overdose, remove barriers to establishing methadone treatment facilities, and address underlying social determinants and barriers to treatment. These changes have the ability to save thousands of lives annually.
Asunto(s)
Buprenorfina/administración & dosificación , Accesibilidad a los Servicios de Salud , Metadona/administración & dosificación , Trastornos Relacionados con Opioides/epidemiología , Buprenorfina/provisión & distribución , Sobredosis de Droga/prevención & control , Política de Salud , Humanos , Metadona/provisión & distribución , Tratamiento de Sustitución de Opiáceos , Epidemia de Opioides/prevención & control , Trastornos Relacionados con Opioides/complicaciones , Determinantes Sociales de la Salud , Estados Unidos/epidemiologíaRESUMEN
This article explores challenges to accessing opioid treatment programs in rural areas, and offers solutions that would ease these problems.
Asunto(s)
Accesibilidad a los Servicios de Salud , Tratamiento de Sustitución de Opiáceos , Trastornos Relacionados con Opioides/tratamiento farmacológico , Servicios de Salud Rural , Analgésicos Opioides/efectos adversos , Buprenorfina/provisión & distribución , Sobredosis de Droga/mortalidad , Necesidades y Demandas de Servicios de Salud , Humanos , Metadona/provisión & distribución , Población Rural , Estados UnidosRESUMEN
Objective: To estimate the incidence of drop out of treatment in patients with access to methadone maintenance treatment and explore the correlation and interaction between insufficient methadone dosage and morphine positive urine on the drop out in Guangxi Zhuang Autonomous Region. Methods: Face to face interview was conducted in 1 031 patients at 3 methadone maintenance treatment clinics in Guangxi. Results: The study included 1 031 participants, 40.6% of them (419/1 031) had stopped treatment. The drop out rates in urine morphine positive group and methadone dosage<100 mg/d group were 57.6% (99/172) and 37.4% (347/929) respectively, higher than those in urine morphine negative group and methadone dosage ≥100 mg/d group (42.3%, 363/859, and 26.5%, 27/102). Orderly logistic regression analysis results showed that after adjusted factors, such as gender, age, marital status, ethnic group, patients who received a dosage less than 100 mg/day (OR=3.05, 95%CI: 1.84-5.06) and had morphine positive urine (OR=2.25, 95%CI: 1.59-3.19) were more likely to drop out of the treatment. Interaction analysis showed that dosage less than 100 mg/d and morphine positive urine during treatment had additive interaction (RERI=256.46, AP=0.87, S= 8.05) and multiplication interaction (OR=2.45, 95%CI: 1.71-3.49). Conclusion: Insufficient dosage and morphine positive urine were significantly correlated with drop out of treatment in patients with access to methadone maintenance treatment.
Asunto(s)
Metadona/uso terapéutico , Dependencia de Morfina/rehabilitación , Morfina/orina , Narcóticos/uso terapéutico , Tratamiento de Sustitución de Opiáceos , Pacientes Desistentes del Tratamiento/estadística & datos numéricos , Adulto , China/epidemiología , Relación Dosis-Respuesta a Droga , Femenino , Accesibilidad a los Servicios de Salud , Humanos , Incidencia , Entrevistas como Asunto , Masculino , Metadona/administración & dosificación , Metadona/provisión & distribución , Dependencia de Morfina/epidemiología , Dependencia de Morfina/orina , Detección de Abuso de Sustancias , Resultado del TratamientoAsunto(s)
Analgésicos Opioides/economía , Dolor Crónico/tratamiento farmacológico , Dolor Crónico/economía , Costos de los Medicamentos , Prescripciones de Medicamentos/economía , Metadona/economía , Medicamentos bajo Prescripción/economía , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/provisión & distribución , Citas y Horarios , Dolor Crónico/diagnóstico , Ahorro de Costo , Análisis Costo-Beneficio , Esquema de Medicación , Humanos , Metadona/administración & dosificación , Metadona/provisión & distribución , Clínicas de Dolor/economía , Medicamentos bajo Prescripción/administración & dosificación , Medicamentos bajo Prescripción/provisión & distribución , Factores de TiempoRESUMEN
BACKGROUND: In the last 20 years, pharmaceutical care has evolved as a modus operandi for community pharmacy. This article tracks the development of pharmaceutical care for drug misusers since 1995 and considers the implications for pharmacy engagement with the wider care team. OBJECTIVE: To survey current community pharmacy service provision for drug misusers, past training and future training needs and compare with data from previous years (1995, 2000 and 2006). METHOD: A cross-sectional postal questionnaire of pharmacy managers in Scotland (n = 1246), and telephone interviews with non-respondents. Results were compared with previous surveys. RESULTS: The response rate was 70% (873) including 13.2% (164) by telephone. More pharmacies dispensed methadone in 2014 (88.5%) than previously, a significant increase across all time points (1995, 2000 and 2006) (P < 0.001). Most pharmacies (88.1%) had some drug misusers registered for the minor ailment scheme. In 2014, 43.4% of pharmacists always reported a drug misuser's non-attendance for opiate replacement treatment (ORT) to the prescriber (36.6% in 2006). If patient intoxication was suspected, medication was always withheld by 47.9% (27.5% in 2006). Pharmacists undertaking training in drug misuse and blood-borne diseases increased significantly since 1995, to 78.6% and 48.7%, respectively, in 2014 (P < 0.001). The preferred topic for future training was communication/engagement with other services. CONCLUSION: Pharmaceutical care for drug misusers has evolved from ORT supply to a more clinical approach. Pharmacists actively monitored ORT patients, managed their minor ailments and increasingly engaged with the wider care team.
Asunto(s)
Metadona/uso terapéutico , Tratamiento de Sustitución de Opiáceos/tendencias , Mal Uso de Medicamentos de Venta con Receta/estadística & datos numéricos , Actitud del Personal de Salud , Estudios Transversales , Femenino , Humanos , Masculino , Metadona/provisión & distribución , Persona de Mediana Edad , Tratamiento de Sustitución de Opiáceos/métodos , Farmacias/tendencias , Farmacéuticos/estadística & datos numéricos , Mal Uso de Medicamentos de Venta con Receta/tendencias , Escocia , Encuestas y CuestionariosAsunto(s)
Infecciones por VIH/prevención & control , Antagonistas de Narcóticos/uso terapéutico , Trastornos Relacionados con Opioides/rehabilitación , Abuso de Sustancias por Vía Intravenosa/rehabilitación , Buprenorfina/provisión & distribución , Buprenorfina/uso terapéutico , Accesibilidad a los Servicios de Salud , Humanos , Metadona/provisión & distribución , Metadona/uso terapéutico , Antagonistas de Narcóticos/provisión & distribución , Tratamiento de Sustitución de OpiáceosAsunto(s)
Analgésicos Opioides/provisión & distribución , Buprenorfina/provisión & distribución , Control de Medicamentos y Narcóticos/legislación & jurisprudencia , Accesibilidad a los Servicios de Salud/legislación & jurisprudencia , Disparidades en Atención de Salud/legislación & jurisprudencia , Legislación de Medicamentos , Metadona/provisión & distribución , Antagonistas de Narcóticos/provisión & distribución , Tratamiento de Sustitución de Opiáceos , Trastornos Relacionados con Opioides/tratamiento farmacológico , Oxicodona/provisión & distribución , Dolor/tratamiento farmacológico , Trastornos Relacionados con Sustancias/terapia , Analgésicos Opioides/efectos adversos , Analgésicos Opioides/uso terapéutico , Buprenorfina/administración & dosificación , Buprenorfina/uso terapéutico , Aprobación de Drogas , Humanos , Metadona/administración & dosificación , Metadona/uso terapéutico , Antagonistas de Narcóticos/administración & dosificación , Antagonistas de Narcóticos/uso terapéutico , Oxicodona/efectos adversos , Oxicodona/uso terapéutico , Medicamentos bajo Prescripción , Estados Unidos , United States Food and Drug AdministrationRESUMEN
In their role as a source of sterile syringes, pharmacies are ideally situated to provide additional services to injection drug users (IDUs). Expanding pharmacy services to IDUs may address the low utilization rates of healthcare services among this population. This qualitative study of active IDUs in San Francisco explored perspectives on proposed health services and interventions offered in pharmacy settings, as well as facilitators and barriers to service delivery. Eleven active IDUs participated in one-on-one semistructured interviews at a community field site and at a local syringe exchange site between February and May 2010. Results revealed that most had reservations about expanding services to pharmacy settings, with reasons ranging from concerns about anonymity to feeling that San Francisco already offers the proposed services in other venues. Of the proposed health services, this group of IDUs prioritized syringe access and disposal, clinical testing and vaccinations, and provision of methadone. Pharmacists' and pharmacy staff's attitudes were identified as a major barrier to IDUs' comfort with accessing services. The findings suggest that although IDUs would like to see some additional services offered within pharmacy settings, this is contingent upon pharmacists and their staff receiving professional development trainings that cultivate sensitivity towards the needs and experiences of IDUs.
Asunto(s)
Infecciones por VIH/prevención & control , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Metadona/provisión & distribución , Programas de Intercambio de Agujas , Farmacia , Abuso de Sustancias por Vía Intravenosa/prevención & control , Jeringas/provisión & distribución , Adolescente , Adulto , Actitud del Personal de Salud , Niño , Atención a la Salud , Consumidores de Drogas , Femenino , Humanos , Masculino , Salud Pública , Calidad de la Atención de Salud , San Francisco , Abuso de Sustancias por Vía Intravenosa/epidemiología , Adulto JovenRESUMEN
AIMS: To explore service provision and the range of problems that New South Wales (NSW) and Victoria (VIC) community pharmacists providing opioid substitution treatment (OST) have experienced with clients and prescribers. DESIGN: ross-sectional postal survey. SETTING: All community pharmacies providing OST in NSW (n = 593) and VIC (n = 393), Australia. PARTICIPANTS: Completed questionnaires were received from 669 pharmacists (68% response rate). MEASUREMENTS: The questionnaire addressed pharmacy characteristics, recent problems experienced with clients including refusal to dose, provision of credit for dispensing fees, termination of treatment, responses of pharmacists to problems experienced with clients, as well as problems experienced with OST prescribers. FINDINGS: In the preceding month, 41% of pharmacists had refused to dose a client for any reason, due most commonly to expired prescriptions (29%), or > or issed doses (23%). Terminating a client's treatment in the past month was reported among 14% of respondents, due most commonly to inappropriate behaviour and missed doses. Treatment termination was reported by a significantly higher proportion of pharmacists in VIC (P < 0.001). Treatment termination in last month was predicted having more clients (P < 0.001), the provision of buprenorphine treatment (P = 0.008), having a separate dosing area (P = 0.021), and being a female pharmacist (P = 0.013). Past month refusal to dose was predicted by the pharmacy being in VIC (P < 0.001) and having more clients (P < 0.001). Problems experienced most commonly in the past month with prescribers were difficulty contacting prescriber (21%) and provision of takeaway doses to clients considered unstable by the pharmacist (19%) (higher in VIC: both P < 0.001). CONCLUSIONS: This study highlights the range of problems experienced by community pharmacists in the delivery of OST and the consequences for people in treatment. Particular attention should be focused upon considering number of clients per pharmacy and improving professional communication between pharmacists and prescribers.
Asunto(s)
Servicios Comunitarios de Farmacia/estadística & datos numéricos , Trastornos Relacionados con Opioides/tratamiento farmacológico , Analgésicos Opioides/economía , Analgésicos Opioides/provisión & distribución , Buprenorfina/economía , Buprenorfina/provisión & distribución , Estudios Transversales , Femenino , Humanos , Relaciones Interprofesionales , Masculino , Cumplimiento de la Medicación/estadística & datos numéricos , Metadona/economía , Metadona/provisión & distribución , Nueva Gales del Sur , Trastornos Relacionados con Opioides/economía , Relaciones Profesional-Paciente , Negativa al Tratamiento/estadística & datos numéricos , Encuestas y Cuestionarios , VictoriaAsunto(s)
Prescripciones de Medicamentos/estadística & datos numéricos , Economía Farmacéutica , Metadona/economía , Metadona/provisión & distribución , Trastornos Relacionados con Opioides/rehabilitación , Canadá , Humanos , Aceptación de la Atención de Salud , Grupo de Atención al Paciente/legislación & jurisprudenciaRESUMEN
INTRODUCTION AND AIMS: Community-based pharmacists (CPs) play a pivotal role in the provision of opioid substitution treatment (OST). This study examined practices, experiences, attitudes and intentions of a sample of South Australian pharmacists involved with the provision of OST. DESIGN AND METHODS: A random sample, stratified by geographic location, of 50 SA CPs were administered a telephone survey. The survey included pharmacist and pharmacy details, current practices, problems experienced, attitudes towards and future intentions in relation to the provision of OST. RESULTS: Pharmacists indicated high levels of support for the OST programme and most (98%) intended to continue providing OST. Sixty-four per cent of all pharmacists, and significantly more rural pharmacists (90%), indicated that they were willing to take on additional clients. Metropolitan pharmacists dosed greater numbers of OST clients (median = 7) than rural pharmacists (median = 4). There was a strong positive correlation between number of regular clients seen and problems experienced by pharmacists. Seventy per cent of pharmacists reported detecting no diversion of pharmacotherapy medication. DISCUSSION AND CONCLUSIONS: Despite reports to the contrary, pharmacists appear to be generally positively predisposed to providing OST. Policies aimed at retaining pharmacists, particularly in resource poor rural areas, could consider embracing a shared-care approach between general practitioners and pharmacists.
Asunto(s)
Actitud del Personal de Salud , Servicios Comunitarios de Farmacia/estadística & datos numéricos , Conocimientos, Actitudes y Práctica en Salud , Trastornos Relacionados con Opioides/rehabilitación , Farmacéuticos/psicología , Adulto , Anciano , Buprenorfina/provisión & distribución , Buprenorfina/uso terapéutico , Atención a la Salud , Demografía , Femenino , Humanos , Masculino , Metadona/provisión & distribución , Metadona/uso terapéutico , Persona de Mediana Edad , Narcóticos/provisión & distribución , Narcóticos/uso terapéutico , Trastornos Relacionados con Opioides/epidemiología , Trastornos Relacionados con Opioides/psicología , Ubicación de la Práctica Profesional , Australia del Sur , Encuestas y Cuestionarios , TeléfonoRESUMEN
BACKGROUND: Diversion of methadone outside treatment programs occurs, yet reasons for use of 'street methadone' are characterized poorly. Self-medication for withdrawal symptoms is one plausible hypothesis. Among HIV-infected drug users, some antiretroviral medications can reduce potency of methadone, yet any association between such effects and the use of supplemental methadone sources remains undetermined. OBJECTIVE: To estimate the frequency and risk factors for use of street methadone. METHODS: Injection drug users (IDUs) recruited through extensive community outreach in 1988-89 and 1994 were followed semi-annually with questionnaires about health history, use of licit and illicit drugs including methadone and HIV-related assays. Analyses were performed using generalized estimating equation logistic regression. RESULTS: Of 2811 IDUs enrolled and eligible for analysis, 493 people reported use of street methadone over 12 316 person-years of follow-up (4.0/100 person-years). In multivariate analyses, street methadone use was more common among women, whites, those 40-59 years old, those who reported withdrawal symptoms, past methadone program attendance (6-12 months before visit), recent heroin injection with or without cocaine (but not cocaine alone), smoking or sniffing heroin and reported trading sex. Street methadone was not associated with HIV infection or treatment. CONCLUSION: The results suggest that older IDUs still using heroin may be using street methadone to treat signs of withdrawal. The absence of a higher rate of street methadone use in HIV seropositive IDUs reveals that antiretroviral/methadone interactions are not a primary determinant of use outside of treatment settings.
Asunto(s)
Analgésicos Opioides/provisión & distribución , Infecciones por VIH/tratamiento farmacológico , Drogas Ilícitas/provisión & distribución , Metadona/provisión & distribución , Abuso de Sustancias por Vía Intravenosa/rehabilitación , Adolescente , Adulto , Analgésicos Opioides/uso terapéutico , Femenino , Humanos , Masculino , Metadona/uso terapéutico , Persona de Mediana Edad , Factores de Riesgo , Síndrome de Abstinencia a Sustancias/etiologíaRESUMEN
Buprenorphine is dispensed primarily in community pharmacies in Victoria, with buprenorphine prescribing expanding nationally. The aim of this paper was to examine issues that affect the delivery of buprenorphine in the community setting. A cross-sectional survey was conducted of 282 pharmacies participating in the methadone and buprenorphine programme across Victoria. Dispensing pharmacists completed the survey, designed to canvass issues around buprenorphine diversion and other issues related to the programme. Themes from the results indicated that there was concern from the majority of pharmacies with the issue of the supervision of buprenorphine and diversion of dispensed doses. The rate of suspected diversion was 1.5 times per 100 doses per month or 33 times per 100 clients per month. Seventy-four per cent of pharmacists indicated that this was a negative aspect of buprenorphine treatment. Frequency of suspected and confirmed diversion was associated with the number of pharmacy clients. Pharmacists' perceptions of issues related to buprenorphine appeared to affect opinions of buprenorphine clients and the buprenorphine programme more generally. Pharmacists believe that a significant level of diversion is occurring. This finding warrants serious attention, particularly in light of the increasing use of buprenorphine nationally and internationally.
Asunto(s)
Actitud del Personal de Salud , Buprenorfina/provisión & distribución , Buprenorfina/uso terapéutico , Servicios Comunitarios de Farmacia/organización & administración , Mal Uso de los Servicios de Salud/estadística & datos numéricos , Dependencia de Heroína/rehabilitación , Antagonistas de Narcóticos/provisión & distribución , Antagonistas de Narcóticos/uso terapéutico , Farmacéuticos/psicología , Farmacéuticos/estadística & datos numéricos , Australia/epidemiología , Áreas de Influencia de Salud , Estudios Transversales , Demografía , Vías de Administración de Medicamentos , Encuestas de Atención de la Salud , Humanos , Metadona/provisión & distribución , Metadona/uso terapéutico , PrevalenciaRESUMEN
BACKGROUND: The UK heroin market is the biggest in Europe and approximately 70% of heroin deaths are due to fatal poisoning. Methadone treatment for heroin addiction in the UK, the 'British system', is unique as it is largely provided by General Practitioners. METHODS: The Office for National Statistics provided data on deaths, the Home Office provided law enforcement data on drug seizures and the Department of Health data on prescriptions. For methadone treatment we calculated the death rate per 1000 patient years. We used Spearman's rank correlation to assess the association between illicit drug seizures for heroin and methadone and deaths. RESULTS: Between 1993 and 2004 there were 7072 deaths involving heroin/morphine (86% males) and 3298 deaths involving methadone (83% male). From 1993-1997, directly age-standardized mortality rates for males were similar for both drugs, increasing from approximately 5 to 15 per million. Mortality rates for heroin continued to increase until 2000, subsequently decreasing from 30 to 20 per million by 2003, and rising again to 24 per million in 2004. In contrast, mortality rates for methadone decreased between 1997 and 2004 to just above 1993 levels. Among females the mortality rate for both drugs was lower than for males throughout the study period, remaining relatively stable. Methadone deaths per 1000 patient years remained similar between 1993 and 1997, after which they fell by three quarters. For both heroin/morphine and methadone, deaths were strongly associated with seizures (Spearmans' coefficient for males: heroin, P = 0.95, P < 0.001 and methadone, P = 0.83, P = 0.0013). CONCLUSIONS: Our study suggests the 'British System' can deliver substantial expansion of treatment without increased mortality risk. The fall in heroin/morphine deaths since 2000 may also be an indication of success of increasing methadone treatment. Data on mortality risk is needed to determine whether increased methadone treatment has reduced drug-related deaths.